Headline
The latest stories from AHA Today.
The Measure Applications Partnership workgroups will meet virtually to discuss performance measures under consideration by the Centers for Medicare & Medicaid Services, including measures related to hospitals’ commitment to addressing health equity as well as severe obstetric complications.
The U.S. Court of Appeals for the Eighth Circuit denied a stay pending appeal of the Missouri district court’s preliminary injunction enjoining the Centers for Medicare & Medicaid Services vaccine mandate in the 10 states that are part of that lawsuit.
The Senate Finance Committee released parts of its updated legislative text for the $1.7 trillion Build Back Better Act, and, as urged by the AHA, the bill does not contain Medicaid Disproportionate Share Hospital cuts that were included the House-passed version of the bill.
Building on its long-standing commitment to health equity, Maryland-based Luminis Health redoubled its efforts during the COVID-19 pandemic to chart a road map to leading as an anti-racist organization, writes Tamiko Stanley, chief diversity, equity and inclusion officer at the organization, a…
Almost 4.6 million people have selected a 2022 health plan through the federally facilitated or state-based marketplaces since open enrollment started Nov. 1, and the Centers for Medicare & Medicaid Services announced.
The Department of Health and Human Services’ Office on Women’s Health recognized 20 organizations, including AHA-member hospitals and health systems, for their effective programs to monitor and provide follow-up care for hypertensive disorders to pregnant and postpartum women.
The House passed the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667), AHA-supported legislation that would authorize grants for programs that offer behavioral health services for front-line health care workers.
The Food and Drug Administration authorized using the combination monoclonal antibody therapy Evusheld to help prevent COVID-19 in certain adults and children with compromised immune systems or a history of severe adverse reaction to a COVID-19 vaccine or its components.
The Food and Drug Administration announced the widely anticipated expansion of Pfizer’s COVID-19 vaccine emergency use authorization to allow booster doses for 16- and 17-year-olds.
The AHA released a new issue of the COVID-19 Snapshot underscoring the persisting challenges facing hospitals and health systems during the ongoing public health emergency.